Global epidemiology of cirrhosis — aetiology, trends and predictions

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(6), С. 388 - 398

Опубликована: Март 28, 2023

Язык: Английский

---

Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2022, Номер 8(1), С. 20 - 30

Опубликована: Ноя. 16, 2022

Язык: Английский

---

MAFLD: How is it different from NAFLD?

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 29(Suppl), С. S17 - S31

Опубликована: Ноя. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Язык: Английский

---

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 28(4), С. 841 - 850

Опубликована: Сен. 19, 2022

Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used Bayesian approach NAFLD through year 2040.Methods: Prevalence data from 245 articles involving 2,699,627 persons were with a hierarchical 2040. Subgroup analyses performed for age, gender, presence metabolic syndrome, region, smoking status. Sensitivity analysis was conducted clinical setting study quality.Results: The forecasted 2040 55.7%, three-fold increase since 1990 43.2% 2020 38.9%. estimated average yearly 2.16%. For those aged <50 years ≥50 years, significantly different (56.7% vs. 61.5%, <i>P</i>=0.52). There significant difference by sex (males: 60% 50%) but trend steeper females (annual percentage change: 2.5% 1.5%, <i>P</i>=0.025). no trends overtime region (<i>P</i>=0.48). rate higher without syndrome (3.8% 0.84%, <i>P</i>=0.003) smokers (1.4% 1.1%, <i>P</i>=0.011). clinical/community (<i>P</i>=0.491) or quality (<i>P</i>=0.85).Conclusion: By 2040, over half adult population is have largest are expected occur women, smokers, syndrome. Intensified efforts needed raise awareness determine long-term solutions addressing driving factors disease.

Язык: Английский

---

Non-alcoholic fatty liver disease: Definition and subtypes

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 29(Suppl), С. S5 - S16

Опубликована: Дек. 28, 2022

Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases worldwide, with a global prevalence approximately 30%. However, NAFLD has been variously reported depending on comorbidities. The rising obesity in both adult and pediatric populations projected to consequently continue increasing prevalence. It major cause chronic including cirrhosis hepatocellular carcinoma (HCC). variety clinical phenotypes heterogeneity due complexity pathogenesis conditions its occurrence, resulting various prognoses. In this article, we briefly described basic definition classified subtypes based current knowledge field.

Язык: Английский

---

Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(12), С. 797 - 809

Опубликована: Авг. 3, 2023

Язык: Английский

---

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Clinical and Molecular Hepatology, Год журнала: 2023, Номер 29(2), С. 320 - 331

Опубликована: Фев. 2, 2023

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although is a well-known risk factor for adverse outcomes like cirrhosis hepatocellular carcinoma, its interactions with virus (HBV) clinical impacts seem complex. presence hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated injury. In contrast, associated co-morbidities diabetes mellitus or obesity increase developing outcomes. These findings implicate that components MAFLD have diverse effects on manifestations CHB. To this end, strategy proposed managing concurrent CHB MAFLD. This review article discusses updated evidence regarding prevalence, between HBV, impacts, management strategies, aiming at optimizing holistic health care in population.

Язык: Английский

---

Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study

Metabolism, Год журнала: 2024, Номер 152, С. 155789 - 155789

Опубликована: Янв. 13, 2024

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease in adults

Nature Reviews Disease Primers, Год журнала: 2025, Номер 11(1)

Опубликована: Март 6, 2025

Язык: Английский

---

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 29(Suppl), С. S43 - S57

Опубликована: Ноя. 23, 2022

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic in United States and worldwide. Though nonalcoholic per se may not be independently associated with an increased risk for all-cause mortality, it a number harmful metabolic factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, sedentary lifestyle, unhealthy diet. The fibrosis stage predictor mortality NAFLD. Mortality individuals NAFLD has been steadily increasing, cause-specific cardiovascular disease, followed by extra-hepatic cancer, liver-related diabetes. High-risk profiles include PNPLA3 I148M polymorphism, low thyroid function hypothyroidism, sarcopenia. Achieving weight loss through adherence to high-quality diet sufficient physical activity important improvement severity benefit survival. Given increasing health burden NAFLD, future studies more long-term data demonstrate independent association between mortality.

Язык: Английский

---